Status:
COMPLETED
The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity
Lead Sponsor:
Laboratoires Vivacy
Conditions:
Aging
Eligibility:
FEMALE
35-65 years
Phase:
NA
Brief Summary
STYLAGE® HydroMax is a CE-marketed hyaluronic acid gel intended to improve skin moisturization and elasticity through injection into the dermis of the face, neck, neckline area and back of the hand. I...
Detailed Description
This is a prospective, single center, randomized, intra-individual study with blinded evaluators assessing the efficacy and safety of STYLAGE® HydroMax on skin moisturization and elasticity on the che...
Eligibility Criteria
Inclusion
- Healthy subject.
- Female between 35 and 65 years.
- Having given freely and expressly her informed consent.
- With signs of cutaneous dryness on the cheeks and neckline area (checked by measurements using Corneometer® \<60 arbitrary unit (AU) on each cheek).
- With signs of a mild to moderate lack of elasticity on face and neckline area following investigator assessment.
- Psychologically able to understand the study related information and to give a written informed consent.
- Affiliated to a health social security system.
- Female of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study and during all the study.
- Agreeing not to change any hormonal treatment (including contraceptive treatment) during the whole study.
- Agreeing to keep their usual cleansing / care products during the whole study period.
- Agreeing to apply a sun protection factor SFP50 cream during non-intensive exposure to sunlight.
Exclusion
- Pregnant or nursing woman or planning a pregnancy during the study.
- With a tattoo, a scar, moles, too many hairs or anything on the studied zones which might interfere with the evaluation.
- Who had been deprived of their freedom by administrative or legal decision or who is under guardianship.
- In a social or sanitary establishment.
- Having received 4500 euros indemnities for participation in researches involving human beings in the 12 previous months, including participation in the present study.
- Participating to another research on human beings or who is in an exclusion period of one.
- Intensive exposure to sunlight or UV-rays within the previous month and foreseen during the study.
- Suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results.
- With known history of or suffering from autoimmune disease and/or immune deficiency.
- Suffering from inflammatory and/or infectious cutaneous disorders in or near the studied zones (herpes, acne, mycosis, papilloma…). Subject with recurrent herpes is not eligible even if asymptomatic at time of inclusion.
- Having history of severe allergy or anaphylactic shock including hypersensitivity to hyaluronic acid or to one of the component of the tested device, antiseptic solution or anaesthesia product if applicable.
- With fructose intolerance.
- With a past history of streptococcal disease, such as acute rheumatic fever or recurrent sore throats.
- Predisposed to keloids or hypertrophic scarring.
- Prone to develop inflammatory skin conditions or having tendency to bleeding disorders.
- Having received treatment with a laser, a dermabrasion, a surgery, a deep chemical peeling or other ablative procedure on the cheeks or the neckline area within the past 12 months prior to study start.
- Having received injection with a resorbable filling product in the cheeks or the neckline area within the past 18 months prior to study start.
- Having received at any time injection with a slowly resorbable filling product (polylactic acid, calcium hydroxyapatite, combinations of hyaluronic acid (HA) and hypromellose, HA and dextran microbeads or HA and TriCalcium Phosphate (TCP), …) or with a non-resorbable filling product (polyacrylamide, silicone, combination of methacrylic polymers and collagen, polymer particles, …).
- Having received at any time a treatment with tensor threads on the face or the neckline area.
- Having started or changed her oral contraceptive or any other hormonal treatment during 12 weeks prior to study start.
- Using medication such as aspirin, NSAIDs (ibuprofen, naproxen, …), antiplatelet agents, anticoagulants, vitamin C within one week prior to study start and agreeing not to take such treatments within 1 week prior to the second and third injections or being a chronic user.
- Undergoing a topical treatment on the test area or a systemic treatment:
- anti-histamines during the 2 weeks prior to study start;
- immunosuppressors and/or corticoids during the 4 weeks prior to study start;
- retinoids during the 6 months prior to study start.
Key Trial Info
Start Date :
September 3 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 8 2020
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT04088006
Start Date
September 3 2019
End Date
July 8 2020
Last Update
August 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laboratoire DERMSCAN
Villeurbanne, Rhône, France, 69100